日期:
2020 年 — 2026 年
2020
2021
2022
2023
2024
2025
2026
影响因子:

Personalizing therapies over the course of hormone receptor-positive/HER2-negative metastatic breast cancer

在激素受体阳性/HER2阴性转移性乳腺癌的治疗过程中,制定个性化治疗方案

Singareeka Raghavendra, Akshara; Damodaran, Senthil; Barcenas, Carlos H; Fuqua, Suzanne A; Layman, Rachel M; Tripathy, Debu

Tucatinib-trastuzumab-capecitabine for treatment of leptomeningeal metastasis in women with HER2(+) breast cancer: TBCRC049 phase 2 study results

Tucatinib-trastuzumab-capecitabine治疗HER2(+)乳腺癌女性软脑膜转移:TBCRC049 II期研究结果

Murthy, Rashmi K; O'Brien, Barbara J; Berry, Donald A; Singareeka-Raghavendra, Akshara; Monroe, Maria Gule; Johnson, Jason; White, Jason; Schwartz-Gomez, Jill; Topletz-Erickson, Ariel; Lobbous, Mina; Riley, Kristen; Melisko, Michelle; Morikawa, Aki; Ferguson, Sherise D; de Groot, John F; Krop, Ian E; Valero, Vicente; Rimawi, Mothaffar F; Wolff, Antonio C; Tripathy, Debu; Lin, Nancy U; Stringer-Reasor, Erica M

Prevalence of HER2-low status and outcomes in early-stage HER2-negative breast cancer

HER2低表达状态的患病率及早期HER2阴性乳腺癌的预后

Singareeka Raghavendra, Akshara; Liu, Diane D; Pasyar, Sarah; Damodaran, Senthil; Shen, Yu; Mouabbi, Jason A; Barcenas, Carlos H; Tripathy, Debu

Assessment of Socio-Demographic and Clinical Characteristics of Stroke Patients of a Tertiary Hospital in Bangladesh: A Cross-Sectional Study

孟加拉国一家三级医院卒中患者社会人口学和临床特征评估:一项横断面研究

Shankar Devnath Debu, Sree Shib; Alam, Ryadul; Eti, Israt Jahan; Mitra, Dipak Kumar

Risk Stratification for Trastuzumab-Induced Cardiac Dysfunction and Potential Implications for Surveillance

曲妥珠单抗诱发心脏功能障碍的风险分层及其对监测的潜在意义

Ali, Abdelrahman; Koutroumpakis, Efstratios; Song, Juhee; Booser, Daniel; Barcenas, Carlos H; Tripathy, Debu; Barac, Ana; Palaskas, Nicolas L; Deswal, Anita

Antitumor Activity and Biomarker Analysis for TROP2 Antibody-Drug Conjugate Datopotamab Deruxtecan in Patient-Derived Breast Cancer Xenograft Models.

TROP2 抗体-药物偶联物 Datopotamab Deruxtecan 在患者来源的乳腺癌异种移植模型中的抗肿瘤活性和生物标志物分析

Meric-Bernstam Funda, Yuca Erkan, Evans Kurt W, Zhao Ming, Maejima Takanori, Karibe Tsuyoshi, Raso Maria Gabriela, Tang Ximing, Zheng Xiaofeng, Rizvi Yasmeen Qamar, Akcakanat Argun, Scott Stephen M, Wang Bailiang, Byers Lauren A, Tripathy Debu, Okajima Daisuke, Damodaran Senthil

Clinical Characteristics and Survival Outcomes of Metastatic Invasive Lobular and Ductal Carcinoma

转移性浸润性小叶癌和导管癌的临床特征和生存结局

Raghavendra, Akshara S; Bassett, Roland Jr; Damodaran, Senthil; Barcenas, Carlos H; Mouabbi, Jason A; Layman, Rachel; Tripathy, Debu

IL-6 predicts CDK4/6 inhibitor resistance, identifying STAT3 as a target in HR + /HER2-negative metastatic breast cancer.

IL-6 预测 CDK4/6 抑制剂耐药性,确定 STAT3 为 HR+/HER2 阴性转移性乳腺癌的靶点

Kettner Nicole M, Bui Tuyen N, Navarro-Yepes Juliana, Ghotbaldini Sanaz, Quintela Bethanie, Luo Catherine K, Lam Nghi, Rao Xiayu, Raghavendra Akshara Singareeka, Wang Yan, Azizian Nancy, Kris Eckols T, Kasembeli Moses Makokha, Evans Kurt, Yi Min, Wingate Hannah, Wang Jing, Sahin Aysegul A, Meric-Bernstam Funda, Hunt Kelly K, Damodaran Senthil, Tweardy David J, Tripathy Debu, Keyomarsi Khandan

Early tumor volume reduction by breast DCE MRI predicts pathologic complete response to neoadjuvant therapy in triple negative breast cancer

乳腺动态增强磁共振成像早期肿瘤体积缩小可预测三阴性乳腺癌新辅助治疗后的病理完全缓解

Guirguis, Mary S; Adrada, Beatriz E; Yam, Clinton; Tripathy, Debu; Candelaria, Rosalind; Yang, Wei; Patel, Miral; Moseley, Tanya; Perez, Frances; Whitman, Gary J; Leung, Jessica W T; Le-Petross, Huong; Lane, Deanna L; Huo, Lei; Litton, Jennifer K; Valero, Vicente; Hunt, Kelly K; Arun, Banu; Mohamed, Rania; Sun, Jia; Korkut, Anil; Xu, Zhan; Pashapoor, Sanaz; White, Jason; Son, Jong Bum; Thompson, Alastair; Wei, Peng; Ma, Jingfei; Moulder, Stacy; Rauch, Gaiane M

Phase I trial of hydroxychloroquine to enhance palbociclib and letrozole efficacy in ER+/HER2- breast cancer

羟氯喹增强哌柏西利和来曲唑对 ER+/HER2- 乳腺癌疗效的 I 期试验

Akshara Singareeka Raghavendra, Nicole M Kettner, Danielle Kwiatkowski, Senthil Damodaran, Yan Wang, David Ramirez, Dan S Gombos, Kelly K Hunt, Yu Shen, Khandan Keyomarsi, Debu Tripathy